Cerezyme
Payments companies reported to CMS as associated with Cerezyme. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cerezyme, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cerezyme
These are the largest totals companies reported as associated with Cerezyme. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Stuart Ditchek | Brooklyn, NY | General Practice | $123,892.28 |
| Kyrieckos Aleck | Albuquerque, NM | Clinical Genetics (M.D.) | $114,986.46 |
| Maurizio Ghisoli | Dallas, TX | Pediatric Hematology-Oncology | $90,220.23 |
| Joseph Ray | Galveston, TX | Clinical Genetics (M.D.) | $81,412.57 |
| Ravi Kamath | Fairfax, VA | Diagnostic Radiology | $70,524.92 |
| Neil Nagovski | Miami, FL | Hematology & Oncology | $65,071.94 |
| Dmitriy Niyazov | Durham, NC | Clinical Genetics (M.D.) | $45,910.66 |
| Linda Spencer | Troy, MI | Nurse Practitioner | $41,138.50 |
| Neal Weinreb | Coral Springs, FL | $31,776.97 | |
| David Stockton | Detroit, MI | Internal Medicine | $30,580.67 |
Prescribed Cerezyme?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.